Similar Search Results

Mergers and alliances in pharmaceuticals : effects on innovation and R&D productivity

Grabowski, Henry G.; Kyle, Margaret K. - In: The economics of corporate governance and mergers, (pp. 262-287). 2008

Persistent link: https://www.econbiz.de/10003757960

Generic competition and market exclusivity periods in pharmaceuticals

Grabowski, Henry G.; Kyle, Margaret K. - In: Managerial and decision economics : MDE ; the … 28 (2007) 4/5, pp. 491-502

Persistent link: https://www.econbiz.de/10003543732

Health reform and pharmaceutical innovation

Grabowski, Henry G. - 1994

Persistent link: https://www.econbiz.de/10013538447

The role of firm characteristics in pharmaceutical product launches

Kyle, Margaret K. - In: The Rand journal of economics 37 (2006) 3, pp. 602-618

Persistent link: https://www.econbiz.de/10003463005

Pharmaceutical price controls and entry strategies

Kyle, Margaret K. - In: The review of economics and statistics 89 (2007) 1, pp. 88-99

Persistent link: https://www.econbiz.de/10003438455

Competition and the efficiency of markets for technology

Allain, Marie-Laure; Henry, Emeric; Kyle, Margaret K. - In: Management science : journal of the Institute for … 62 (2016) 4, pp. 1000-1019

Persistent link: https://www.econbiz.de/10011460538

Markets for pharmaceutical products

Scott Morton, Fiona; Kyle, Margaret K. - 2012

Persistent link: https://www.econbiz.de/10011498384

Are important innovations rewarded? : evidence from pharmaceutical markets

Kyle, Margaret K. - In: Review of industrial organization : RIO 53 (2018) 1, pp. 211-234

Persistent link: https://www.econbiz.de/10012009110

Strategic interaction among governments in the provision of a global public good

Kyle, Margaret K.; Ridley, David B.; Zhang, Su - In: Journal of public economics 156 (2017), pp. 185-199

Persistent link: https://www.econbiz.de/10011824105

Intellectual Property Rights and Access to Innovation : Evidence from TRIPS

Kyle, Margaret - 2014

We examine the effect of pharmaceutical patent protection on the speed of drug launch, price, and quantity in 60 countries from 2000-2013. The World Trade Organization required its member countries to implement a minimum level of patent protection within a specified time period as part of the...

Persistent link: https://www.econbiz.de/10012457867